U.S. Household Products Stock News

Omnicell (OMCL) has been drawing attention after a period of share price weakness, with the stock down about 21% over the past month and 18% over the past 3 months. See our latest analysis for Omnicell. At the current share price of $36.03, Omnicell’s momentum has been weak recently, with the share price return down over the past month and year to date, while the 1 year total shareholder return remains positive but longer term total shareholder returns are still deeply negative. If Omnicell’s...

Emerson Electric stock has delivered a strong 79.7% return over the past 3 years. At around US$162 per share it now screens as roughly fairly valued on earnings multiples rather than an obvious bargain, while its broader valuation checks lean on the expensive side. Recent contract wins and AI focused moves keep growth expectations in play, so the key issue for you is whether the current price already reflects that optimism. Over the last 3 years Emerson Electric has returned 79.7%, which...

Aptiv stock has had a difficult run over the past few years, yet some of the valuation checks still suggest it is not obviously expensive at today’s price. That mix of weak long term returns and mixed valuation signals is what investors now need to weigh. Aptiv shareholders have seen the stock decline 61.9% over the past 5 years, which raises questions about how much of the bad news is already reflected in the price. The recent share price reaction to softer expectations and market...

nVent Electric stock has produced very strong long term returns, yet the current valuation checks and intrinsic value estimate now both point to the shares trading at a premium. For investors, that sets up a clear pricing question around how much optimism is already reflected in the current level. Over the past 5 years, nVent Electric has delivered a return of about 4.7x, which places a lot of focus on whether the current share price already reflects much of that success. Expectations for...

Edgewell Personal Care (NYSE:EPC) lowered its earnings guidance for fiscal 2026 following its latest quarterly results. The revised outlook signals a shift in management expectations for the year and points to potential pressures on the business. Investors are assessing what the updated guidance could mean for Edgewell Personal Care's profitability and capital allocation plans. To put Edgewell Personal Care's updated outlook in context, consider exploring other consumer products stocks...

Westlake (WLK) is back on investors’ radar after reporting second quarter 2026 results that showed a move from a net loss a year ago to net income of US$260 million. See our latest analysis for Westlake. Despite the return to profitability and a regular dividend that has been paid and increased over 22 years, Westlake’s recent 90 day share price return declined 11.79% and its 1 year total shareholder return declined 3.60%. This signals fading momentum after a stronger year to date share price...

Why PBF Energy Is Back On Investors' Radar Recent attention on PBF Energy (PBF) stems from progress in its Refining Business Improvement program, a positive analyst ranking, and supportive sentiment from strong peer performance across the refining and marketing sector. See our latest analysis for PBF Energy. PBF Energy's share price has moved sharply higher in recent months, with a 19.63% 1 month share price return, 75.56% 3 month share price return, and a 163.13% year to date share price...

Vistance Networks has delivered a very large 3 year return, yet its valuation checks point to a stock that now looks closer to fairly priced than deeply discounted. The Discounted Cash Flow (DCF) intrinsic value estimate is broadly in line with the current share price, while market multiples still lean supportive. Vistance Networks has returned about 6x over the past 3 years, which sets a high bar for any further gains to be justified by fundamentals. The completed sale of the Ruckus segment...

Bank of America stock has returned 136.3% over the past three years, and current valuation checks suggest the intrinsic value estimate still sits above the market price. This raises the question of how much of the recent optimism is already reflected in today’s US$63.89 share price. A 136.3% gain over three years shows that Bank of America has rewarded investors strongly, which can increase the risk that expectations in the price get ahead of the fundamentals. The planned US$250b Critical...

Tariff threats between the US and Canada have shifted from background noise to a real risk, with new duties of up to 50% on about $20b of cross border trade now on the table. That puts logistics and customs brokers directly in the spotlight. For investors, this could reshape who handles the flow of goods. This article walks through three stocks exposed to the latest trade shock and explains why they may matter for a diversified portfolio. The stocks in the article below are only a starting...

Elastic stock has rallied over the past few years, but long term holders are still facing a decline over five years. Current checks also show an unusual split between its intrinsic value estimate from a Discounted Cash Flow (DCF) model and what the market multiples suggest. The DCF points to Elastic trading at a discount to an estimated intrinsic value, yet the market based multiples appear expensive, leaving investors weighing which signal to trust. Over the last five years, Elastic shares...

The upcoming second quarter earnings report for Target (TGT) is in focus as investors look for evidence that the recent improvement in comparable sales and the retailer's broader turnaround efforts can continue. See our latest analysis for Target. Target's recent share price return of 50.24% year to date and 18.68% over 90 days points to strong positive momentum. However, the 5 year total shareholder return of a 30.12% decline highlights how long term holders have experienced a very different...

Astrana Health (ASTH) drew investor attention after releasing second quarter 2026 results and fresh guidance, alongside plans for further tuck in acquisitions in its Care Delivery expansion markets. See our latest analysis for Astrana Health. Astrana Health's recent earnings beat and updated 2026 guidance appear to be feeding into a strong year to date share price return of 57.61%. However, the 30 day share price return is down 11.55% and the 5 year total shareholder return is down 44.72%,...

In the past quarter, QCR Holdings reported revenue growth of 13.4% year on year, beating analyst expectations, while strong loan production, a rebound in capital markets revenue, and wealth management contributions helped deliver record GAAP EPS alongside lower-than-anticipated noninterest expenses. This performance highlights how QCR Holdings’ diversified banking and fee-based businesses can support earnings resilience when multiple segments contribute simultaneously to revenue and cost...

Virtu Financial recently launched notional order execution capabilities for 10b-18 corporate buyback programs, enabling clients to execute repurchases based on specific dollar amounts for tighter budget control and flexible commission treatment. Truist Bank’s internal analysis indicated that Virtu’s new notional execution outperformed a competing provider on benchmark quality and total notional value executed, highlighting the product’s differentiation in a niche market. We’ll now examine...

American Superconductor stock has retreated 39.9% over the past year, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) model currently points to around 12.5% upside from the recent share price of US$32.13. With market multiples also screening the stock as undervalued, investors are weighing whether the recent pullback has moved the price below what the cash flow outlook implies. Over the last 3 years, American Superconductor has returned 254.2%. This means long term...

With 30 year and 10 year Treasury yields pushing toward levels not seen in decades, the bond market is quietly rewriting the playbook for investors. Higher long term rates can pressure many stocks, yet they can also reshape the income potential and risk profile of others. This article looks at how that backdrop ties into three U.S. life insurers and annuity providers exposed to these yield moves, and what that could mean for your watchlist. The three stocks covered below are only a starting...

Why Paylocity’s latest earnings and partnerships matter for investors Paylocity Holding (PCTY) has been in focus after reporting fourth quarter and full year 2026 earnings alongside new partnerships that tie its human capital platform more tightly into AI driven recruiting tools. The company’s recent collaboration with HireQuotient and RocketReach links Paylocity’s cloud based HR, payroll and spend management suite to data powered sourcing and screening. This lets customers automate parts of...

StepStone Group (STEP) is back in focus after reporting first quarter results for the period ended June 30, 2026. The company posted higher revenue alongside a wider net loss that may raise fresh questions for investors. See our latest analysis for StepStone Group. Despite the wider loss in the latest quarter, StepStone Group’s share price has risen 10.86% over the past month, although the share price is still down 27.52% year to date and the 1 year total shareholder return is down 16.18%,...

Walmart stock has delivered a strong 142.1% total return over the past five years, while the latest valuation work using a Discounted Cash Flow (DCF) approach suggests the shares trade at a premium to that intrinsic value estimate. Over five years, Walmart has returned 142.1%, which puts recent gains under the spotlight as investors assess how much future cash flow is already reflected in the price. Growth expectations around e-commerce, advertising and automation partnerships such as the...

Earlier this year, DexCom highlighted that expanded insurance reimbursement now gives its continuous glucose monitoring systems access to a large group of type 2 non-insulin diabetes patients, while recent Q2 clinical data and product updates underscored the medical benefits of broader CGM use. This combination of wider coverage and strong evidence base is reshaping expectations for DexCom’s long-term demand profile and business mix, even as competition and pricing uncertainties remain...

Vera Therapeutics, Inc. reported past second quarter 2026 results showing a net loss of US$109.47 million, up from US$76.53 million a year earlier, with basic loss per share from continuing operations widening to US$1.52 from US$1.20. For the first half of 2026, the company’s net loss rose to US$230.51 million from US$128.23 million, highlighting a materially higher cash burn and pressure on per-share results at this stage of its development. Next, we will examine how this widening net loss...

Over the last 7 days, the United States market has remained flat, but it is up 19% over the past year with earnings expected to grow by 17% per annum over the next few years. In this context of steady growth and optimistic projections, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and potential for expansion in a dynamic industry landscape.

In the last week, the United States market has stayed flat, yet it has experienced a notable 19% increase over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of steady growth and positive earnings outlooks, identifying undervalued stocks can present opportunities for investors to capitalize on potential market inefficiencies.